"Ozempic and Weight-Loss Drugs: Boosting the US Economy"

Goldman Sachs strategists predict that the increased use of weight-loss drugs like Ozempic in the US could potentially boost the nation's gross domestic product by an extra 1% over the next decade, equivalent to about $360 billion per year, due to the economic burden of poor health on the labor supply. Drug companies like Novo Nordisk and Eli Lilly are racing to develop obesity drugs, with the market expected to exceed $100 billion by 2030. Goldman projects that 10-70 million Americans could be taking weight-loss drugs by 2028, potentially leading to significant economic spillovers if obesity rates decrease.